跳至主要内容
临床试验/NCT05472428
NCT05472428已完成1 期

Autologous Bone Marrow Mononuclear Cell Administration in the Treatment of Neurologic Sequela in Children With Spina Bifida

Vinmec Research Institute of Stem Cell and Gene Technology2 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2016年7月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
11
试验地点
2
主要终点
Adverse events and serious adverse events

研究概览

简要总结

The aim of this study was to evaluate the safety and efficacy of autologous bone marrow mononuclear cell infusion in the management of neurological sequelae in children with spina bifida

详细描述

The aim of this study was to evaluate the safety and effectiveness of autologous bone marrow mononuclear cells in 11 patients with spina bifida at Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam from 2016 to 2020

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

盲法说明

Open Label

入排标准

年龄范围
6 Months 至 15 Years(Child)
性别
All
接受健康志愿者

入选标准

  • The patient who was diagnosed with lumbar spina bifida underwent spinal cord close-up surgery.
  • Both genders.
  • Aged between 6 months and 15 years old.
  • Exhibited bowel disorders (constipation, fecal incontinence) and urinary dysfunction (urinary retention or leakage).

排除标准

  • Vertebrae clefts in the chest, neck, and other spinal locations.
  • Coagulopathy.
  • Acute and chronic infection.
  • Kidney function disorder, liver failure
  • Patients with complex cardiovascular diseases (including valvular heart disease, cardiomyopathy, arrhythmia, congenital heart disease, hypertrophy syndrome).

结局指标

主要结局

Adverse events and serious adverse events

时间窗: up to the 12-month period following treatment

Incidence of the adverse events or serious adverse events after infusion

次要结局

  • Lower limb motor functions(up to the 12-month period following treatment)
  • Rectoanal inhibitory reflex(up to the 12-month period following treatment)
  • Bladder sensation(up to the 12-month period following treatment)
  • Urinary retention(up to the 12-month period following treatment)
  • Bristol stool scale(up to the 12-month period following treatment)
  • Urinary incontinence(up to the 12-month period following treatment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验